20 citations
,
July 2013 in “PLoS ONE” Targeting EGFR may help reduce hair loss from chemotherapy.
43 citations
,
March 2017 in “Drug Design Development and Therapy” The new nanoparticles could improve melanoma treatment by working better than current options.
4 citations
,
February 2019 in “Breast Cancer Research and Treatment” DHL-HisZnNa may help reduce hair loss from chemotherapy, but more research is needed.
June 2025 in “CA A Cancer Journal for Clinicians” Transgender men need personalized cancer care and continued testosterone therapy for well-being.
2 citations
,
October 2018 in “Springer eBooks” Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
21 citations
,
November 2018 in “Journal of the European Academy of Dermatology and Venereology” The combination of encorafenib and binimetinib caused few skin issues.
1 citations
,
July 2014 in “International Journal of Dermatology” A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.
July 2024 in “Journal of Investigative Dermatology” A new test helps find drugs to treat head and neck cancer by targeting c-Rel.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.
56 citations
,
January 2023 in “Genes & Diseases” Repurposing existing drugs and using micronutrients may effectively target cancer stem cells and improve cancer treatment.
6 citations
,
July 2015 in “JAAD Case Reports” Doxycycline can effectively treat hair loss caused by EGFR inhibitors.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology” October 2020 in “Der Hautarzt” Tofacitinib helped regrow hair in a woman with alopecia areata.
6 citations
,
December 2021 in “Journal of Cancer Research and Therapeutics” The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
November 2025 in “Eurasian journal of applied biotechnology” Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
40 citations
,
July 2023 in “Clinical Pharmacology & Therapeutics” Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.
49 citations
,
December 2022 in “Pharmacological Reviews” Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.
28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
1 citations
,
January 2009 in “Actas Dermo-Sifiliográficas” Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.
17 citations
,
January 2015 in “Dermatology online journal” A patient's grey hair regained color during treatment with adalimumab.
March 2005 in “Journal of the American Academy of Dermatology” Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
4 citations
,
April 2014 in “Lasers in Surgery and Medicine” TRASER effectively targets blood vessels and hair follicles for potential use in vascular and hair removal treatments.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” Hair growth supplements do not reduce the effectiveness of the breast cancer treatment tamoxifen.
May 2025 in “Dermatology Online Journal” Erlotinib can cause excessive eyelash growth.
58 citations
,
September 2019 in “EMBO Molecular Medicine” CDK4/6 inhibitors can protect hair cells from chemotherapy damage.
More research is needed to understand chemotherapy-induced hair loss and its phases.
September 2006 in “Experimental Dermatology” Targeting multiple pathways and understanding genetic mutations are crucial for effective melanoma therapy.